Abstract:Abstract Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington’s disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are often discrepant and longitudinal studies are lacking. Proton magnetic resonance spectroscopy metabolites may represent a source of biomarkers, thus their relationship with established markers of disease progression require further exploration to assess prognostic value and elucidate pathways associated with neurodegeneration. In a prospective single-site controlled cohort study with standardized collection of CSF, blood, phenotypic and volumetric imaging data, we used 3 T proton magnetic resonance spectroscopy in conjunction with the linear combination of model spectra method to quantify seven metabolites (total n-acetylaspartate, total creatine, total choline, myo-inositol, GABA, glutamate and glutathione) in the putamen of 59 participants at baseline (15 healthy controls, 15 premanifest and 29 manifest Huntington’s disease gene expansion carriers) and 48 participants at 2-year follow-up (12 healthy controls, 13 premanifest and 23 manifest Huntington’s disease gene expansion carriers). Intergroup differences in concentration and associations with CSF and plasma biomarkers; including neurofilament light chain and mutant Huntingtin, volumetric imaging markers; namely whole brain, caudate, grey matter and white matter volume, measures of disease progression and cognitive decline, were assessed cross-sectionally using generalized linear models and partial correlation. We report no significant groupwise differences in metabolite concentration at baseline but found total creatine and total n-acetylaspartate to be significantly reduced in manifest compared with premanifest participants at follow-up. Additionally, total creatine and myo-inositol displayed significant associations with reduced caudate volume across both time points in gene expansion carriers. Although relationships were observed between proton magnetic resonance spectroscopy metabolites and biofluid measures, these were not consistent across time points. To further assess prognostic value, we examined whether baseline proton magnetic resonance spectroscopy values, or rate of change, predicted subsequent change in established measures of disease progression. Several associations were found but were inconsistent across known indicators of disease progression. Finally, longitudinal mixed-effects models revealed glutamine + glutamate to display a slow linear decrease over time in gene expansion carriers. Altogether, our findings show some evidence of reduced total n-acetylaspartate and total creatine as the disease progresses and cross-sectional associations between select metabolites, namely total creatine and myo-inositol, and markers of disease progression, potentially highlighting the proposed roles of neuroinflammation and metabolic dysfunction in disease pathogenesis. However, the absence of consistent group differences, inconsistency between baseline and follow-up, and lack of clear longitudinal change suggests that proton magnetic resonance spectroscopy metabolites have limited potential as Huntington’s disease biomarkers.

Plasma Homovanillic Acid and Prolactin in Huntington’s Disease

Diagnostic Potential of Alternations of Bile Acid Profiles in the Plasma of Patients with Huntington's Disease

F10 Quantifying Putative Biomarkers of Huntington Disease in Blood and Urine by Selected Reaction Monitoring Mass Spectrometry

The clinical, imaging and biological features of psychosis in Han Chinese patients with Huntington's disease

Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders

Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.

Evaluation of Blood Glial Fibrillary Acidic Protein As a Potential Marker in Huntington's Disease

Huntington disease: natural history, biomarkers and prospects for therapeutics

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease

Preserved VPS13A distribution and expression in Huntington's disease: divergent mechanisms of action for similar movement disorders?

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

[Psychiatric symptoms of Huntington's disease]

Identifying and verifying Huntington's disease subtypes: Clinical features, neuroimaging, and cytokine changes

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

Mental health symptoms among those affected by Huntington's disease: A cross-sectional study

High levels of mutant huntingtin protein in tear fluid from Huntington’s Disease Gene Expansion Carriers

Gray Matter Alterations in Huntington's Disease: A Meta-Analysis of VBM Neuroimaging Studies.

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

Decreased Hypothalamic Prohormone Convertase Expression in Huntington Disease Patients.

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.